Every year, many people in the United States get a blood test that measures LDL, which is often called "bad" cholesterol. New research from Northwestern Medicine shows that another test, called apolipoprotein B (ApoB), can do a better job of finding those who need stronger treatment to lower their risk of heart attacks and strokes.
The study, published in JAMA, compared three ways to decide if a patient should get more aggressive cholesterol‑lowering medicine. The methods were: aiming for an LDL level below 100 mg/dL, aiming for a non‑HDL level below 118 mg/dL, and aiming for an ApoB level below 78.7 mg/dL.
Researchers used a computer model that represented 250,000 U.S. adults who could qualify for statin therapy but had not yet had heart disease. The model followed each group for a whole lifetime, looking at heart attacks, strokes, years lived, quality of life, and medical costs.
Results showed that the ApoB‑guided approach gave the best outcomes. It prevented more heart attacks and strokes, added more healthy years, and did so at a cost that the researchers called affordable.
Why does ApoB work better? Unlike LDL or non‑HDL tests, ApoB counts the total number of cholesterol‑carrying particles that can stick to artery walls and form plaques. More particles mean higher risk. By measuring the particle count directly, doctors get a clearer picture of heart danger.
Even with this evidence, many doctors still do not use the ApoB test. One reason is that it usually needs an extra blood draw beyond the standard cholesterol panel, which can add cost and inconvenience.
The new American Heart Association guidelines suggest starting cholesterol‑lowering therapy at younger ages for many people. This makes it even more important to pick the right test, so the right patients receive the right treatment.
In short, the ApoB test appears to be a smarter, cost‑effective way to decide who should get stronger medicines to keep hearts healthy.